By Diagnostics World Staff
November 7, 2016 | Myriad Genetics announced that it will submit its BRACAnalysis CDx test for approval by Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) in parallel with the PMDA review of AstraZeneca’s novel PARP inhibitor, Olaparib.
BRACAnalysis CDx is the leading genetic test to identify patients who are likely to benefit from treatment with Olaparib, which is a novel PARP inhibitor that targets tumor DNA repair pathway deficiencies to preferentially kill cancer cells.
"BRACAnalysis CDx launched precision medicine for ovarian cancer patients by identifying patients more likely to respond to PARP inhibitors," said Mark C. Capone, president and CEO, Myriad Genetics in a statement.
Today’s announcement builds on a long-term companion diagnostic collaboration with AstraZeneca that began in 2007. In December 2014, the U.S. Food and Drug Administration (FDA) approved BRACAnalysis CDx to identify ovarian cancer patients who may be appropriate for treatment with Lynparza (Olaparib). It was the first time the FDA had approved a laboratory developed test (LDT) under the premarket approval application process.